Metformin alleviates lung ischemia-reperfusion injury in a rat lung transplantation model

• Published in: Experimental lung research 2024, Vol.50 (1), p.15-24
• Main Authors: Yu, Huizhi, Wang, Jing, Liu, Mingzhao, Hu, Chunlan, Sun, Jiaojiao, Xu, Bo, Lu, Shunmei, Huang, Dongxiao, Pang, Qingfeng, Hu, Chunxiao
• Format: Article
• Language: English
• Subjects: Animals; Lung; Lung Injury; Lung Transplantation - adverse effects; Rats; Rats, Inbred Lew; Rats, Sprague-Dawley; Reperfusion Injury - drug therapy; Reperfusion Injury - prevention & control
• ISSN: 0190-2148; 1521-0499
• DOI: 10.1080/01902148.2023.2301615

Lung ischemia-reperfusion injury (LIRI) is among the complications observed after lung transplantation and is associated with morbidity and mortality. Preconditioning of the donor lung before organ retrieval may improve organ quality after transplantation. We investigated whether preconditioning with metformin (Met) ameliorates LIRI after lung transplantation. Twenty Lewis rats were randomly divided into the sham, LIRI, and Met groups. The rats in the LIRI and Met groups received saline and Met, respectively, oral gavage. Subsequently, a donor lung was harvested and kept in cold storage for 8 h. The LIRI and Met groups then underwent left lung transplantation. After 2 h of reperfusion, serum and transplanted lung tissues were examined. The partial pressure of oxygen (PaO ) was greater in the Met group than in the LIRI group. In the Met group, wet-to-dry (W/D) weight ratios, inflammatory factor levels, oxidative stress levels and apoptosis levels were notably decreased. Met protects against ischemia-reperfusion injury after lung transplantation in rats, and its therapeutic effect is associated with its anti-inflammatory, antioxidative, and antiapoptotic properties.